Zepbound or Another GLP-1 Drug Denied? How to Appeal and What to Know as You Age

You have a prescription for Zepbound or another GLP-1 medication. Your insurance company says it won't pay for it. What happens next?

If that sounds familiar, you are not alone. GLP-1 (glucagon-like peptide-1) medications such as Zepbound, Wegovy and Ozempic have gone from headlines to medicine cabinets across the country. About one in eight U.S. adults now takes one, and use is highest among adults ages 50 to 64, according to a November 2025 KFF Health Tracking Poll. Chances are that you, a spouse, a parent, or a close friend has been prescribed one of these drugs and then heard "no" from an insurer.

Coverage has not kept up with demand. Plans vary widely, and even people who meet prescribing guidelines can run into exclusions, prior authorization requirements, step therapy, or formulary restrictions. The 2025 KFF Employer Health Benefits Survey found that only 19 percent of employers with 200 or more workers that offered health benefits covered GLP-1 medications when used primarily for weight loss. Coverage was much more common among the largest employers. Among companies with at least 5,000 workers, 43 percent provided coverage.

Medicare is also changing its approach. For years, federal law barred Medicare prescription drug plans from covering drugs used only for weight loss. A temporary program, the Medicare GLP-1 Bridge, began July 1, 2026, and runs through Dec. 31, 2027. Eligible Medicare Part D enrollees can get Zepbound (KwikPen only), Wegovy, or Foundayo for $50 a month. Eligibility rules and prior authorization still apply, so a "no" is still possible.

A denial does not always end the matter. You may have the right to appeal, depending on your health plan and the reason for the denial. The first step is understanding exactly why your insurer said no.

If you’re nearing retirement, there’s another factor to weigh. GLP1 medications, and the weight loss they often produce, can influence healthy aging. They may also affect the underwriting of LongTerm Care Insurance applications, which many adults ages 45 to 70 pursue to prepare for the costs and burdens of aging and future longterm care.

Why Zepbound and Other GLP-1 Medications Get Denied

GLP-1 medications include several drugs with different FDA-approved uses. Zepbound, the brand name for tirzepatide, is approved for chronic weight management in certain adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Wegovy, the brand name for semaglutide, is approved for chronic weight management in certain adults and children age 12 and older. It also has an FDA-approved indication to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. Other medications in the broader GLP-1 family, including Ozempic and Mounjaro, are approved for Type 2 diabetes, although people taking them may also lose weight.

Those differences matter because health insurance coverage can depend on the medication, diagnosis, and reason it was prescribed. Dr. Robert Kushner, Professor of Medicine and Endocrinology at Northwestern University Feinberg School of Medicine, says the challenge isn't just whether a medication works clinically, but how health plan formularies categorize the indication.

When a drug like Wegovy or Zepbound is prescribed for chronic weight management or cardiovascular risk reduction, patients frequently face steep administrative hurdles compared to someone receiving a diabetes-indicated agent, because commercial and public payers draw strict lines around diagnosis codes." — Dr. Robert Kushner. 

Common reasons for a denial of a GLP-1 prescription include:

• The medication isn't on the plan's formulary.
• The plan excludes medications used for weight management.
• Prior authorization was required but not completed.
• The submitted documentation doesn't satisfy the plan's requirements.
• The patient doesn't meet the plan's clinical criteria.
• Step therapy requires trying another medication first.
• The insurer prefers a different drug.
• Documentation of weight history, previous treatment, or related health conditions is incomplete.

The National Association of Insurance Commissioners (NAIC) notes that some employers exclude GLP-1 medications from their health plans. Others require prior authorization or an obesity-related health condition, such as high blood pressure or high cholesterol, before covering them. Medicare, as noted, has expanded coverage for these medications, for now.

One important question is whether you are dealing with a benefit exclusion or a denial based on medical necessity or coverage criteria. If your employer's health plan specifically excludes weight-management medications, additional medical records may not overcome that exclusion.

If the drug is covered but the insurer says your physician didn't provide enough information, additional documentation could make a difference. Start by reading the denial notice.

Why the Diagnosis Matters

The same drug can have more than one FDA-approved use. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. It became the first medication approved to treat the condition. Wegovy also has multiple FDA-approved indications, including cardiovascular risk reduction in certain adults.

A health plan may cover a medication for one medical condition but not another. Physicians must accurately document why they are prescribing a medication. A diagnosis should never be changed just to obtain insurance coverage. However, incomplete or inaccurate information submitted with a prior authorization can lead to an avoidable denial.

Start With the Denial Letter

Before writing an appeal, determine what the insurance company requires. Review the denial notice and contact the insurer or pharmacy benefit manager if anything is unclear.

Ask why the medication was denied, whether it is on the formulary, what clinical criteria apply, and whether the plan requires prior authorization or step therapy.

Also ask:

• Is a formulary exception available?
• What documentation is missing?
• What is the deadline for an appeal?
• Is expedited review available when medically necessary?
• What external-review rights apply if the internal appeal is unsuccessful?

Keep the denial letter. It identifies the decision you are challenging and should provide instructions for filing an appeal.

How to Appeal a Zepbound or GLP-1 Denial

Appeal procedures vary by health plan, applicable state or federal rules, and the reason coverage was denied. For plans subject to Affordable Care Act appeal protections, HealthCare.gov says consumers generally have 180 days after receiving a denial notice to file an internal appeal. Your denial notice and plan documents should provide the deadline that applies to you.

An appeal should address the insurer's reason for saying no rather than simply arguing that the medication is beneficial. Useful documentation can include:

• The denial notice.
• Relevant medical records.
• Current and previous weight and BMI.
• Obesity-related medical conditions.
• Previous weight-management efforts.
• Medications previously tried.
• Reasons another medication may not be appropriate.
• A physician's letter of medical necessity.
• Relevant clinical evidence.
• The health plan's coverage criteria.

A personal statement can explain how the medical condition affects daily life, but the appeal should remain focused on clinical evidence and the requirements of the health plan.

Your Physician Can Strengthen the Appeal

A physician's involvement can be especially important when an insurer questions medical necessity or says the original prior authorization didn't contain enough information. A letter of medical necessity can document the diagnosis, weight and BMI history, related health conditions, previous treatments, and the reason a particular medication was selected.

If an insurer wants a patient to use another drug first, the physician can explain why that medication may be inappropriate when there is a legitimate clinical reason. Clinical research can support the appeal, but simply sending an insurer a collection of studies isn't enough. The evidence should relate to the patient's medical circumstances.

For example, the SURMOUNT-1 trial studied 2,539 adults with obesity or overweight plus a weight-related complication who did not have diabetes. Participants receiving tirzepatide experienced substantially greater average weight reduction than those receiving placebo over 72 weeks.

Getting Professional Help With an Appeal

Some patients manage the process themselves or with help from their physician's office. State insurance departments and consumer assistance programs may also provide information. Professional appeal services are another option.

One example is Claimable, a physician-led company that prepares customized health insurance appeals, including appeals involving GLP-1 medications. Claimable says it combines medical history, clinical evidence, and insurance policy information to prepare an appeal. As of September 2026, the company lists a standard price of $39.95 plus shipping for appeals that don't qualify for sponsored no-cost assistance.

Warris Bokhari, MD, Claimable's CEO and co-founder, told LTC News that an insurance denial should not necessarily be the end of the road for a patient who has been prescribed a GLP-1 medication.

When coverage is denied, patients and their providers should understand the reason for the decision, review the plan's requirements carefully, and use the available appeal process to present the clinical evidence supporting the treatment. A well-documented appeal can give the patient an opportunity to have their case properly reconsidered.” — Dr. Warris Bokhari.

No appeal service can guarantee an insurance company will reverse its decision; however, professional help can speed up the process and reduce the stress of insurance denials. You should review the company's fees, services, and terms before paying for help.

Do Insurance Appeals Actually Work?

National data doesn’t support claims that most health insurance appeals succeed; however, this review covers all appeals, not just those handled by professional services.

KFF examined claims from qualified health plans sold through HealthCare.gov in 2024. Insurers denied 19 percent of in-network claims. Consumers appealed fewer than 1 percent of those denials. Among the internal appeals that were filed, insurers upheld 66 percent of their original denials. That means roughly one-third were reversed at the internal-appeal stage.

Those numbers include many types of medical claims. They aren't specific to Zepbound or GLP-1 medications and cannot predict whether an individual appeal will succeed. KFF identified at least 5,881 external appeals in the same year, but incomplete data prevented it from calculating a reliable overall success rate for external reviews.

Professional services will point out that this is a reason to consider getting help with your appeal.

If the Insurance Company Still Says No

Some denials qualify for an independent external review. Under federal standards, external review can apply to certain decisions involving medical judgment, including whether treatment is medically necessary or appropriate. It may also apply to some decisions involving experimental or investigational treatment.

HealthCare.gov says a request for external review generally must be filed within four months of receiving the applicable denial or final determination. When an independent external reviewer overturns an eligible denial, the health plan generally must accept the decision.

You may also be able to contact your state insurance department or consumer assistance program. Employer-sponsored plans governed by ERISA can involve additional federal procedures.

How Long Can an Appeal Take?

For health plans subject to federal ACA appeal standards, an internal appeal generally must be completed within:

• 30 days for a service that hasn't yet been received.
• 60 days for a service that has already been received.

Urgent cases have expedited procedures. HealthCare.gov says a final appeal decision in an urgent situation must be provided as quickly as the medical condition requires and at least within four business days after the request is received.

A standard external review generally must be completed within 45 days. An expedited external review can be completed within 72 hours or sooner when medically required. Rules can vary, so follow the instructions and deadlines provided by the health plan.

Medicare GLP-1 Coverage Changed in 2026

As mentioned above, access to GLP-1 medications is increasingly an aging issue as more people taking the drugs reach Medicare eligibility. On July 1, 2026, the Centers for Medicare & Medicaid Services launched the temporary Medicare GLP-1 Bridge for eligible Medicare Part D beneficiaries.

If you are eligible, you can obtain certain GLP-1 medications for weight management for a $50 monthly copayment. The program currently includes certain formulations of Wegovy and Foundayo and the Zepbound KwikPen. The demonstration is scheduled to continue through Dec. 31, 2027.

Not everyone with Medicare qualifies. The reason a drug is prescribed also matters. Zepbound prescribed for moderate-to-severe obstructive sleep apnea in an adult with obesity is already a Medicare Part D-coverable use. CMS says prescriptions for indications already coverable under Part D aren't eligible for the Bridge on that basis. They remain subject to the applicable Part D coverage and formulary rules.

GLP-1 Drugs and Healthy Aging

For older adults, successful weight management involves more than reaching a lower number on the scale. Muscle and strength matter. People tend to lose muscle mass and strength as they age.

Dr. Mooyeon OhPark, a rehabilitation physician and chief medical officer at Burke Rehabilitation Hospital, told AARP that adults ages 40 to 80 lose nearly 40% of their muscle mass. Muscle strength declines even faster, she said — at almost twice the rate of muscle loss.

There are so many older adults who cannot even get out of a chair without using their hands, and that in and of itself is a fall risk. Strength and balance are really important to preserving long-term independence."— Dr. Mooyeon Oh-Park.

The National Institute on Aging says physical activity can help protect against age-related loss of muscle mass, strength, and function. Maintaining strength can make everyday activities easier, reduce fall risk and help older adults remain independent. That's particularly important for someone experiencing substantial weight loss.

Physicians, nurses, dietitians, therapists and other care team members may consider nutrition, adequate protein, resistance exercise, physical activity and existing health conditions when developing a weight-management plan.

Dr. Sharon Brangman, a distinguished service professor of medicine and director of the Center of Excellence for Aging and Alzheimer’s Disease at Upstate Medical University, says the focus in treating older adults should shift from the scale to physical capability. Preserving functional capacity, the strength and stamina needed to walk, climb stairs, and handle daily tasks independently, is as critical to longevity and quality of life as managing weight or metabolic measures.

"Aggressive weight management or chronic illness alone does not insulate an individual from the physical realities of aging, making long-term care planning a necessary consideration regardless of weight status." — Dr. Sharon Brangman.

For someone in their 50s, 60s or 70s, preserving the ability to walk, climb stairs, get out of a chair, dress, bathe and perform other everyday activities can be as important as losing excess weight. Controlling obesity and related chronic conditions is part of healthy aging. It doesn't eliminate the possibility of eventually needing long-term care.

Learn More: What is long-term care?

GLP-1 Use Can Affect Long-Term Care Insurance Underwriting

People considering Long-Term Care Insurance should understand another consequence of significant weight loss. Taking Zepbound, Wegovy, Ozempic, Mounjaro, or another GLP-1 medication does not automatically make someone uninsurable, but GLP-1 medications will impact LTC Insurance underwriting, and every insurance company has its own rules.

The medication itself may not even be the primary underwriting concern. Long-Term Care Insurance companies medically underwrite applicants because they evaluate your overall health and how that impacts your risk above the average of needing extended care.

Underwriters can review your medical history, prescriptions, height and weight, chronic conditions, mobility, cognitive health, and recent health changes. In some situations, underwriters may add back part of your weight loss, depending on how long you have maintained the weight loss.

When someone uses a GLP-1 medication, an underwriter will want to know why it was prescribed, how much weight the person lost, how recently the weight was lost, and whether it has remained stable. The underlying medical condition or conditions also matter. Someone taking a GLP-1 for obesity without diabetes presents a different medical history from someone taking a GLP-1 who also has Type 2 diabetes, cardiovascular disease, sleep apnea, or other health problems.

An experienced Long-Term Care Insurance specialist who works with multiple insurance companies can review your health history before you submit a formal application and determine how different carriers may view GLP-1 use and recent weight loss.

👉How do you apply for Long-Term Care Insurance?

Don't Assume GLP-1 Insurance Denial Is the Final Answer

If your insurance company denies Zepbound or another GLP-1 medication, find out why before deciding what to do next. A plan exclusion is different from a missing prior authorization. A formulary restriction is different from a medical-necessity decision.

Get the reason in writing. Review the plan's requirements. Ask your physician to correct incomplete information when necessary. Keep your medical records and file any appeal before the deadline. Use professional help if necessary. There is a longer-term consideration, too. Weight management can be an important part of healthy aging, but maintaining muscle, strength, and mobility matters. If Long-Term Care Insurance is part of your retirement planning, substantial recent weight loss with a GLP-1 medication can also affect underwriting.

Your health history, why you're taking the medication, how much weight you've lost, and how long your weight has stayed stable can all play a role.